Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)

Abstract

How does once-weekly subcutaneous tirzepatide affect maintenance of weight loss in individuals with obesity or overweight? Methods : SURMOUNT-4 is a phase 3, double-blind, 88-week study that investigates the maximum tolerated dose (MTD) of tirzepatide (10 mg or 15 mg QW), compared with placebo, on the maintenance of weight loss for 52 weeks after an initial 36-week open-label tirzepatide lead-in treatment period. In the study, participants without T2DM and with obesity (BMI ≥30 kg/m^2) or overweight (BMI ≥27 kg/m^2) with at least 1 weight-related comorbid condition were enrolled. The efficacy estimand was used to assess efficacy which represented the average treatment effect, prior to treatment discontinuation. Results : 803 participants enrolled in the lead-in period and 670 were randomized to continue tirzepatide MTD (N=335) or switch to placebo (N=335). For randomized participants, the mean weight loss was 20.9% following 36-week open-label treatment. SURMOUNT-4 met the primary endpoint. From week 36 to week 88, those taking tirzepatide had an additional weight change of -6.7%, while those taking placebo had a mean weight regain of 14.8%. The percentage of participants at 88 weeks who maintained ≥80% of the weight loss during the lead-in period was 93.4% with tirzepatide and 13.5% with placebo. In addition, participants who remained on tirzepatide achieved a total of 26.0% mean weight loss over the 88-week period. The most frequent adverse events with tirzepatide were gast…

Overview

Integrity signals

Registry

Crossref · 10.1055/s-0044-1785403

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Still being checked.

Cited by

See all 23

Metadata

Authors
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & Ebert, T.
Affiliations
  • Weill Cornell Medicine (US)
  • University of Glasgow (GB)
  • University of Texas McGovern Medical School, University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, Houston, Texas , United States
  • Louisville Metabolic and Atherosclerosis Research Center (US)
  • McMaster University (CA)
  • China Medical University Hospital (TW)
  • Eli Lilly (United States) (US)
  • University Hospital Leipzig (DE)
Venue
Diabetologie und Stoffwechsel
Published
2024-04
Volume
19
Issue
S 01
Pages
S84-S85
ISSN
  • 1861-9002 (ISSN-L)
  • 1861-9010
OpenAlex
W4394936275
Cited by
13
References
0
Citations by year
2026: 2 · 2025: 6 · 2024: 5
FWCI
3.71
Type
journal article
Language
de
Open access
closed
Locations
Diabetologie und Stoffwechsel (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
tirzepatide, obesity, overweight, weight loss maintenance, weight regain, maximum tolerated dose, weight-related comorbidities, gastrointestinal adverse effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). https://app.cochat.ai/papers/10.1055/s-0044-1785403
The paper
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & Ebert, T. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). Diabetologie und Stoffwechsel. https://doi.org/10.1055/s-0044-1785403

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.